These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 18854285)

  • 21. Delayed complete remission in a patient with multiple myeloma.
    Ria R; Vacca A; Mangialardi G; Dammacco F
    Eur J Clin Invest; 2008 Dec; 38(12):966-8. PubMed ID: 19021723
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Primary effusion lymphoma in the absence of HIV infection--clinical presentation and management.
    Klepfish A; Zuckermann B; Schattner A
    QJM; 2015 Jun; 108(6):481-8. PubMed ID: 25413797
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I trial of bortezomib in combination with rituximab-HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma.
    Romaguera JE; Fayad LE; McLaughlin P; Pro B; Rodriguez A; Wang M; Weaver P; Hartig K; Kwak LW; Feldman T; Smith J; Ford P; Goldberg S; Pecora A; Goy A
    Br J Haematol; 2010 Oct; 151(1):47-53. PubMed ID: 20735402
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment with bortezomib in a patient with heavily pretreated refractory T-cell lymphoblastic lymphoma.
    Mai W; Meng H; Jin J; Wang L
    Eur J Haematol; 2006 Nov; 77(5):445-7. PubMed ID: 16930138
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bortezomib in combination with pegylated liposomal doxorubicin for the treatment of multiple myeloma.
    Manochakian R; Miller KC; Chanan-Khan AA
    Clin Lymphoma Myeloma; 2007 Jan; 7(4):266-71. PubMed ID: 17324333
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prespecified candidate biomarkers identify follicular lymphoma patients who achieved longer progression-free survival with bortezomib-rituximab versus rituximab.
    Coiffier B; Li W; Henitz ED; Karkera JD; Favis R; Gaffney D; Shapiro A; Theocharous P; Elsayed YA; van de Velde H; Schaffer ME; Osmanov EA; Hong X; Scheliga A; Mayer J; Offner F; Rule S; Teixeira A; Romejko-Jarosinska J; de Vos S; Crump M; Shpilberg O; Zinzani PL; Cakana A; Esseltine DL; Mulligan G; Ricci D
    Clin Cancer Res; 2013 May; 19(9):2551-61. PubMed ID: 23549871
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Weekly bortezomib, pegylated liposomal doxorubicin, and dexamethasone is a safe and effective therapy for elderly patients with relapsed/refractory multiple myeloma.
    Gozzetti A; Fabbri A; Oliva S; Marchini E; Bocchia M; Defina M; Lauria F
    Clin Lymphoma Myeloma Leuk; 2010 Feb; 10(1):68-72. PubMed ID: 20223732
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Primary effusion lymphoma.
    Chen YB; Rahemtullah A; Hochberg E
    Oncologist; 2007 May; 12(5):569-76. PubMed ID: 17522245
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Complete remission in 4 patients with human herpesvirus 8-associated multicentric Castleman disease using rituximab and liposomal doxorubicin, a novel chemotherapy combination.
    Peker D; Martinez AE; Schwartz MA; Cusnir M
    Clin Adv Hematol Oncol; 2012 Mar; 10(3):204-6. PubMed ID: 22402431
    [No Abstract]   [Full Text] [Related]  

  • 30. Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma.
    de Vos S; Goy A; Dakhil SR; Saleh MN; McLaughlin P; Belt R; Flowers CR; Knapp M; Hart L; Patel-Donnelly D; Glenn M; Gregory SA; Holladay C; Zhang T; Boral AL
    J Clin Oncol; 2009 Oct; 27(30):5023-30. PubMed ID: 19770386
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Brief-duration rituximab/chemotherapy followed by maintenance rituximab in patients with diffuse large B-cell lymphoma who are poor candidates for R-CHOP chemotherapy: a phase II trial of the Sarah Cannon Oncology Research Consortium.
    Hainsworth JD; Flinn IW; Spigel DR; Clark BL; Griner PL; Vazquez ER; Doss HH; Shipley D; Franco LA; Burris HA; Greco FA;
    Clin Lymphoma Myeloma Leuk; 2010 Feb; 10(1):44-50. PubMed ID: 20223728
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antitumor effects of bortezomib (PS-341) on primary effusion lymphomas.
    An J; Sun Y; Fisher M; Rettig MB
    Leukemia; 2004 Oct; 18(10):1699-704. PubMed ID: 15343345
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Primary Effusion Lymphoma-like Lymphoma in a Patient with Neurofibromatosis Type 1.
    Oki M; Nanao T; Shinoda T; Tsuda A; Yasuda A; Seki T; Ozawa H; Nakamura N; Takagi A
    Tokai J Exp Clin Med; 2016 Sep; 41(3):123-9. PubMed ID: 27628603
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intracavitary cidofovir for human herpes virus-8-associated primary effusion lymphoma in an HIV-negative patient.
    Stingaciu S; Ticchioni M; Sudaka I; Haudebourg J; Mounier N
    Clin Adv Hematol Oncol; 2010 May; 8(5):367-74. PubMed ID: 20551896
    [No Abstract]   [Full Text] [Related]  

  • 35. Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: a retrospective study.
    Zinzani PL; Stefoni V; Finolezzi E; Brusamolino E; Cabras MG; Chiappella A; Salvi F; Rossi A; Broccoli A; Martelli M
    Clin Lymphoma Myeloma; 2009 Oct; 9(5):381-5. PubMed ID: 19858058
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Human herpesvirus 8-unrelated primary effusion lymphoma-like lymphoma: report of a rare case and review of 54 cases in the literature.
    Wu W; Youm W; Rezk SA; Zhao X
    Am J Clin Pathol; 2013 Aug; 140(2):258-73. PubMed ID: 23897264
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HHV-8/KSHV-negative and CD20-positive primary effusion lymphoma successfully treated by pleural drainage followed by chemotherapy containing rituximab.
    Terasaki Y; Okumura H; Saito K; Sato Y; Yoshino T; Ichinohasama R; Ishida Y
    Intern Med; 2008; 47(24):2175-8. PubMed ID: 19075546
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression.
    Orlowski RZ; Nagler A; Sonneveld P; Bladé J; Hajek R; Spencer A; San Miguel J; Robak T; Dmoszynska A; Horvath N; Spicka I; Sutherland HJ; Suvorov AN; Zhuang SH; Parekh T; Xiu L; Yuan Z; Rackoff W; Harousseau JL
    J Clin Oncol; 2007 Sep; 25(25):3892-901. PubMed ID: 17679727
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Human herpesvirus 8 (HHV-8)-associated peritoneal primary effusion lymphoma (PEL) in two HIV-negative elderly patients.
    Boulanger E; Hermine O; Fermand JP; Radford-Weiss I; Brousse N; Meignin V; Gessain A
    Am J Hematol; 2004 May; 76(1):88-91. PubMed ID: 15114607
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Primary effusion lymphoma is a rare cause of pleural effusion].
    Saxild S; Schjødt I; Hutchings M; Brændstrup P
    Ugeskr Laeger; 2016 Feb; 178(5):V10150795. PubMed ID: 26857301
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.